135 related articles for article (PubMed ID: 7868749)
21. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
22. Telomerase activity and expression of apoptosis and anti-apoptosis regulators in the progression pathway of human melanoma.
Yang P; Becker D
Int J Oncol; 2000 Nov; 17(5):913-9. PubMed ID: 11029492
[TBL] [Abstract][Full Text] [Related]
23. Morphometric, DNA, and proliferating cell nuclear antigen measurements in benign melanocytic lesions and cutaneous malignant melanoma.
Björnhagen V; Bonfoco E; Brahme EM; Lindholm J; Auer G
Am J Dermatopathol; 1994 Dec; 16(6):615-23. PubMed ID: 7864299
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical study of p53 protein expression in Spitz nevus as compared with other melanocytic lesions.
Bergman R; Shemer A; Levy R; Friedman-Birnbaum R; Trau H; Lichtig C
Am J Dermatopathol; 1995 Dec; 17(6):547-50. PubMed ID: 8599466
[TBL] [Abstract][Full Text] [Related]
25. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
26. Staining of melanocytic neoplasms by melanoma antigen recognized by T cells.
Mehregan DR; Hamzavi I
Am J Dermatopathol; 2000 Jun; 22(3):247-50. PubMed ID: 10871068
[TBL] [Abstract][Full Text] [Related]
27. [Immunohistochemical analysis of ras gene expression in human melanomas and melanocytic nevi].
Yasuda H
Hokkaido Igaku Zasshi; 1989 May; 64(3):243-53. PubMed ID: 2670726
[TBL] [Abstract][Full Text] [Related]
28. bcl-2 expression in melanocytic nevi. Insights into the biology of dermal maturation.
Morales-Ducret CR; van de Rijn M; Smoller BR
Arch Dermatol; 1995 Aug; 131(8):915-8. PubMed ID: 7632063
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical studies of conjunctival nevi and melanomas.
Jakobiec FA; Bhat P; Colby KA
Arch Ophthalmol; 2010 Feb; 128(2):174-83. PubMed ID: 20142539
[TBL] [Abstract][Full Text] [Related]
30. Malignant melanoma within an intradermal nevus.
Tajima Y; Nakajima T; Sugano I; Nagao K; Kondo Y
Am J Dermatopathol; 1994 Jun; 16(3):301-6. PubMed ID: 7943639
[TBL] [Abstract][Full Text] [Related]
31. Expression of bcl-2 protein and Ki-67 nuclear proliferation antigen in benign and malignant cutaneous T-cell infiltrates.
Dummer R; Michie SA; Kell D; Gould JW; Haeffner AC; Smoller BR; Warnke RA; Wood GS
J Cutan Pathol; 1995 Feb; 22(1):11-7. PubMed ID: 7751472
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.
Rudolph P; Lappe T; Schubert C; Schmidt D; Parwaresch RM; Christophers E
Am J Pathol; 1995 Dec; 147(6):1615-25. PubMed ID: 7495287
[TBL] [Abstract][Full Text] [Related]
33. Proliferation antigens in cutaneous melanocytic tumors--an immunohistochemical study comparing the transferrin receptor and the Ki 67 antigen.
Soyer HP; Smolle J; Smolle-Juettner FM; Kerl H
Dermatologica; 1989; 179(1):3-9. PubMed ID: 2569990
[TBL] [Abstract][Full Text] [Related]
34. Primary melanoma of the skin and cutaneous melanomatous metastases: comparative histologic features and immunophenotypes.
Guerriere-Kovach PM; Hunt EL; Patterson JW; Glembocki DJ; English JC; Wick MR
Am J Clin Pathol; 2004 Jul; 122(1):70-7. PubMed ID: 15272532
[TBL] [Abstract][Full Text] [Related]
35. Utility of a proliferation marker in distinguishing between benign naevocellular naevi and naevocellular naevus-like lesions with malignant properties.
Kanter L; Blegen H; Wejde J; Lagerlöf B; Larsson O
Melanoma Res; 1995 Oct; 5(5):345-50. PubMed ID: 8541725
[TBL] [Abstract][Full Text] [Related]
36. Human monoclonal antibodies that distinguish cutaneous malignant melanomas from benign nevi in fixed tissue sections.
Imam A; Mitchell MS; Modlin RL; Taylor CR; Kempf RA; Kan-Mitchell J
J Invest Dermatol; 1986 Feb; 86(2):145-8. PubMed ID: 3528308
[TBL] [Abstract][Full Text] [Related]
37. Expression of the ets-1 proto-oncogene in melanocytic lesions.
Keehn CA; Smoller BR; Morgan MB
Mod Pathol; 2003 Aug; 16(8):772-7. PubMed ID: 12920221
[TBL] [Abstract][Full Text] [Related]
38. Interleukin (IL)-1 alpha- and -1 beta-, IL-6-, and tumor necrosis factor-alpha-like immunoreactivities in human common and dysplastic nevocellular nevi and malignant melanoma.
Ahmed AA; Nordlind K; Hedblad M; Lagerholm B; Schultzberg M; Lidén S
Am J Dermatopathol; 1995 Jun; 17(3):222-9. PubMed ID: 8599429
[TBL] [Abstract][Full Text] [Related]
39. Melanocytic activation in HIV-1 disease: HMB-45 staining in common acquired nevi. Military Medical Consortium for the Advancement of Retroviral Research.
Smith KJ; Skelton HG; Heimer W; Baxter D; Angritt P; Frisman D; Wagner KF
J Am Acad Dermatol; 1993 Oct; 29(4):539-44. PubMed ID: 7691905
[TBL] [Abstract][Full Text] [Related]
40. Heat shock protein 27 is expressed in normal and malignant human melanocytes in vivo.
Kang SH; Fung MA; Gandour-Edwards R; Reilly D; Dizon T; Grahn J; Isseroff RR
J Cutan Pathol; 2004 Nov; 31(10):665-71. PubMed ID: 15491326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
